Review History


To increase transparency, PeerJ operates a system of 'optional signed reviews and history'. This takes two forms: (1) peer reviewers are encouraged, but not required, to provide their names (if they do so, then their profile page records the articles they have reviewed), and (2) authors are given the option of reproducing their entire peer review history alongside their published article (in which case the complete peer review process is provided, including revisions, rebuttal letters and editor decision letters).

New to public reviews? Learn more about optional signed reviews and how to write a better rebuttal letter.

Summary

  • The initial submission of this article was received on May 9th, 2016 and was peer-reviewed by 2 reviewers and the Academic Editor.
  • The Academic Editor made their initial decision on June 29th, 2016.
  • The first revision was submitted on September 15th, 2016 and was reviewed by the Academic Editor.
  • The article was Accepted by the Academic Editor on September 15th, 2016.

Version 0.2 (accepted)

· · Academic Editor

Accept

Dear Ana,
Thank you for your submission to PeerJ. Your manuscript has been accepted for publication. Congratulations!

Krystyna Dąbrowska

Version 0.1 (original submission)

· · Academic Editor

Major Revisions

In my opinion the crucial improvement that needs to be done in this study is the increase of the number of patients when presenting gene polymorphism-related conclusions. This was also pointed out by the reviewer. I hope you will find all the recommendations helpful.

·

Basic reporting

Zoran Bogdanović and colleagues investigated the possible influence of the suggested IL-6 and Il-28 genetic biomarkers on the progression of HCV disease in crotaian patients in the study entitled “The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection
among intravenous drug users in Croatia”. The authors discovered that Patients showed a significantly better response to treatment according to the number of copies of the C allele carried at rs1800795-IL6.


I appreciate the time and effort put to this study by the authors; however there is one major concern about this study which is that the number of patients used in this study is a bit small to draw solid conclusions out of the study. Therefore, I recommend increasing the number of patients to at least 150-200 patients.
-Minor issues: include an agarose gel picture for the IL-28 gene.

Experimental design

the study design is ok.

Validity of the findings

No comments

Comments for the author

No comments

·

Basic reporting

Introduce treatment options in "Introduction". Patients in this work used standard therapy based in pegylated interferon and ribavirin. However, new direct acting antivirals (DAAs) were introduced to hepatitis C therapy and must to be cited.
More references must to be included in some specific parts (there are notes on "track changes" .doc file).

Experimental design

Describe response type classification on "Methods". Comment if relapser patients were included in non-responder group.

Validity of the findings

No comments

Comments for the author

This article is relevant even though another groups reported these SNPs association. The article is well writen but must to be revised. Most important points are highlighted in the attached file.

All text and materials provided via this peer-review history page are made available under a Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.